SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-259244
Filing Date
2022-10-07
Accepted
2022-10-07 08:01:02
Documents
12
Period of Report
2022-10-07
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d325235d8k.htm   iXBRL 8-K 50841
  Complete submission text file 0001193125-22-259244.txt   172894

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA hznp-20221007.xsd EX-101.SCH 2876
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE hznp-20221007_lab.xml EX-101.LAB 17169
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hznp-20221007_pre.xml EX-101.PRE 10802
6 EXTRACTED XBRL INSTANCE DOCUMENT d325235d8k_htm.xml XML 3349
Mailing Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4
Business Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100
Horizon Therapeutics Public Ltd Co (Filer) CIK: 0001492426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35238 | Film No.: 221299325
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences